Molecular pathology of breast tumors: Diagnostic and actionable genetic alterations Review
| Authors: | Ross, D. S.; Pareja, F. |
| Review Title: | Molecular pathology of breast tumors: Diagnostic and actionable genetic alterations |
| Keywords: | mitogen activated protein kinase; gene mutation; gene translocation; somatic mutation; review; doxorubicin; cancer combination chemotherapy; monotherapy; solid tumor; paclitaxel; disease free survival; cancer diagnosis; biomarkers; gene; homologous recombination; gene overexpression; ovary cancer; breast cancer; gene amplification; gene expression profiling; epidermal growth factor receptor 2; aromatase inhibitor; cyclophosphamide; food and drug administration; phosphatidylinositol 3 kinase; tumor marker; oncogene h ras; cancer hormone therapy; molecular marker; tumor suppressor gene; gene rearrangement; cytidine deaminase; mismatch repair; microsatellite instability; breast tumor; gene fusion; gonadorelin agonist; cancer classification; estrogen receptor; adenoid cystic carcinoma; trastuzumab; metastatic breast cancer; drug sensitivity; pik3ca gene; lapatinib; antineoplastic hormone agonists and antagonists; resistance; her2; neratinib; pertuzumab; olaparib; akt1 gene; programmed death 1 ligand 1; programmed death 1 receptor; molecular pathology; pten gene; molecular diagnosis; triple negative breast cancer; pleomorphic adenoma; idh2 gene; hmga2 gene; selective estrogen receptor modulator; trastuzumab emtansine; plag1 gene; immune checkpoint inhibitor; high throughput sequencing; erbb2 gene; her2 gene; mapk signaling; advanced breast cancer; estrogen receptor positive breast cancer; human epidermal growth factor receptor 2 positive breast cancer; rucaparib; mucoepidermoid tumor; invasive breast cancer; luminal a breast cancer; human; circulating tumor dna; palbociclib; pembrolizumab; cdh1 gene; alpelisib; abemaciclib; estrogen receptor negative breast cancer; ribociclib; luminal b breast cancer; atezolizumab; entrectinib; liquid biopsy; ntrk3 gene; personalized cancer therapy; breast cancer molecular subtype; progesterone receptor negative breast cancer; apolipoprotein b mrna editing enzyme catalytic polypeptide like; larotrectinib; ntrk1 gene; ntrk2 gene; talazoparib; esr1 gene; human epidermal growth factor receptor 2 negative breast cancer; etv6 gene; secretory breast carcinoma; myb gene; molecular fingerprinting; ntrk gene; crtc1 gene; maml2 gene; capivasertib; mutation profiling; mechanisms of resistance; hormone receptor-positive, her2-negative breast cancer; invasive lobular breast carcinoma; adenomyoepithelioma of the breast; mybl1 gene; breast tall cell carcinoma; nfib gene |
| Journal Title: | Clinics in Laboratory Medicine |
| Volume: | 44 |
| Issue: | 2 |
| ISSN: | 0272-2712 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-06-01 |
| Start Page: | 255 |
| End Page: | 275 |
| Language: | English |
| DOI: | 10.1016/j.cll.2023.08.001 |
| PROVIDER: | scopus |
| PUBMED: | 38821644 |
| DOI/URL: | |
| Notes: | Review -- MSK corresponding author is Dara Ross -- Source: Scopus |
